Skip to main content
Erschienen in: Annals of Surgical Oncology 7/2018

11.05.2018 | Gastrointestinal Oncology

Borrmann Type 1 Cancer is Associated with a High Recurrence Rate in Locally Advanced Gastric Cancer

verfasst von: Ji Hyun Kim, MD, Ph.D., Han Hong Lee, MD, Ph.D., Ho Seok Seo, MD, Yoon Ju Jung, MD, Cho Hyun Park, MD, Ph.D.

Erschienen in: Annals of Surgical Oncology | Ausgabe 7/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

This study aimed to investigate the clinicopathologic characteristics and outcomes of Borrmann type 1 gastric cancer and evaluate its clinical significance in advanced gastric cancer compared with Borrmann types 2 and 3 cancer.

Methods

Between January 1989 and December 2013, 1949 patients with advanced gastric cancer who underwent curative gastrectomy at our institution were enrolled in the study.

Results

Of the 1949 patients, 59 (3%) exhibited Borrmann type 1 cancer, characterized by a large size, rare serosal invasion, lower lymph node involvement, location in the upper third of the stomach, intestinal type, and differentiated histology. The recurrence rate was higher for Borrmann type 1 than for Borrmann types 2 and 3 cancer. In addition, more than half of the Borrmann type 1 recurrences showed a hematogenous pattern. However, overall survival did not differ significantly among the three cancer types. In the multivariate analysis, Borrmann type 1 cancer, with tumor depth, node metastasis, and vascular invasion, was an independent risk factor associated with recurrence. Particularly, Borrmann type 1 cancer showed a worse prognosis in both overall survival and recurrence-free survival than the other Borrmann types in the upper third of the stomach.

Conclusions

Borrmann type 1 gastric cancer is associated with a higher recurrence rate than Borrmann types 2 and 3, but not with a difference in the overall survival rate.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
2.
Zurück zum Zitat Marrelli D, Morgagni P, de Manzoni G, Coniglio A, Marchet A, et al. Prognostic value of the 7th AJCC/UICC TNM classification of noncardia gastric cancer: analysis of a large series from specialized Western centers. Ann Surg. 2012;255:486–91.CrossRefPubMed Marrelli D, Morgagni P, de Manzoni G, Coniglio A, Marchet A, et al. Prognostic value of the 7th AJCC/UICC TNM classification of noncardia gastric cancer: analysis of a large series from specialized Western centers. Ann Surg. 2012;255:486–91.CrossRefPubMed
3.
Zurück zum Zitat Hayashi T, Yoshikawa T, Bonam K, Sue-Ling HM, Taguri M, et al. The superiority of the seventh edition of the TNM classification depends on the overall survival of the patient cohort: comparative analysis of the sixth and seventh TNM editions in patients with gastric cancer from Japan and the United Kingdom. Cancer. 2013;119:1330–7. Hayashi T, Yoshikawa T, Bonam K, Sue-Ling HM, Taguri M, et al. The superiority of the seventh edition of the TNM classification depends on the overall survival of the patient cohort: comparative analysis of the sixth and seventh TNM editions in patients with gastric cancer from Japan and the United Kingdom. Cancer. 2013;119:1330–7.
4.
Zurück zum Zitat Huang JY, Xu YY, Li M, Sun Z, Zhu Z, et al. The prognostic impact of occult lymph node metastasis in node-negative gastric cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2013;20:3927–34.CrossRefPubMed Huang JY, Xu YY, Li M, Sun Z, Zhu Z, et al. The prognostic impact of occult lymph node metastasis in node-negative gastric cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2013;20:3927–34.CrossRefPubMed
5.
Zurück zum Zitat Li C, Oh SJ, Kim S, Hyung WJ, Yan M, et al. Macroscopic Borrmann type as a simple prognostic indicator in patients with advanced gastric cancer. Oncology. 2009;77:197–204.CrossRefPubMed Li C, Oh SJ, Kim S, Hyung WJ, Yan M, et al. Macroscopic Borrmann type as a simple prognostic indicator in patients with advanced gastric cancer. Oncology. 2009;77:197–204.CrossRefPubMed
6.
Zurück zum Zitat Yamashita K, Sakuramoto S, Katada N, Kikuchi S, Watanabe M. Simple prognostic indicators using macroscopic features and age in advanced gastric cancer. Hepatogastroenterology. 2014;61:512–7.PubMed Yamashita K, Sakuramoto S, Katada N, Kikuchi S, Watanabe M. Simple prognostic indicators using macroscopic features and age in advanced gastric cancer. Hepatogastroenterology. 2014;61:512–7.PubMed
7.
Zurück zum Zitat Yamashita K, Hosoda K, Katada N, Moriya H, Mieno H, et al. Survival outcome of Borrmann type IV gastric cancer potentially improved by multimodality treatment. Anticancer Res. 2015;35:897–906.PubMed Yamashita K, Hosoda K, Katada N, Moriya H, Mieno H, et al. Survival outcome of Borrmann type IV gastric cancer potentially improved by multimodality treatment. Anticancer Res. 2015;35:897–906.PubMed
8.
Zurück zum Zitat Yamashita K, Ema A, Hosoda K, Mieno H, Moriya H, et al. Macroscopic appearance of type IV and giant type III is a high risk for a poor prognosis in pathological stage II/III advanced gastric cancer with postoperative adjuvant chemotherapy. World J Gastrointest Oncol. 2017;9:166–75.CrossRefPubMedPubMedCentral Yamashita K, Ema A, Hosoda K, Mieno H, Moriya H, et al. Macroscopic appearance of type IV and giant type III is a high risk for a poor prognosis in pathological stage II/III advanced gastric cancer with postoperative adjuvant chemotherapy. World J Gastrointest Oncol. 2017;9:166–75.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Luo Y, Gao P, Song Y, Sun J, Huang X, et al. Clinicopathologic characteristics and prognosis of Borrmann type IV gastric cancer: a meta-analysis. World J Surg Oncol. 2016;14:49.CrossRefPubMedPubMedCentral Luo Y, Gao P, Song Y, Sun J, Huang X, et al. Clinicopathologic characteristics and prognosis of Borrmann type IV gastric cancer: a meta-analysis. World J Surg Oncol. 2016;14:49.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Kim EY, Yoo HM, Song KY, Park CH. Limited significance of curative surgery in Borrmann type IV gastric cancer. Med Oncol. 2016;33:69.CrossRefPubMed Kim EY, Yoo HM, Song KY, Park CH. Limited significance of curative surgery in Borrmann type IV gastric cancer. Med Oncol. 2016;33:69.CrossRefPubMed
11.
Zurück zum Zitat Huang JY, Wang ZN, Lu CY, Miao ZF, Zhu Z, et al. Borrmann type IV gastric cancer should be classified as pT4b disease. J Surg Res. 2016;203:258–67.CrossRefPubMed Huang JY, Wang ZN, Lu CY, Miao ZF, Zhu Z, et al. Borrmann type IV gastric cancer should be classified as pT4b disease. J Surg Res. 2016;203:258–67.CrossRefPubMed
12.
Zurück zum Zitat Chen JH, Wu CW, Lo SS, Li AF, Hsieh MC, et al. Lymph node metastasis as a single predictor in patients with Borrmann type I gastric cancer. Hepatogastroenterology. 2007;54:981–4.PubMed Chen JH, Wu CW, Lo SS, Li AF, Hsieh MC, et al. Lymph node metastasis as a single predictor in patients with Borrmann type I gastric cancer. Hepatogastroenterology. 2007;54:981–4.PubMed
13.
Zurück zum Zitat Washington K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol. 2010;17:3077–9.CrossRefPubMed Washington K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol. 2010;17:3077–9.CrossRefPubMed
14.
Zurück zum Zitat Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14:113–23.CrossRef Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14:113–23.CrossRef
15.
Zurück zum Zitat Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg. 1998;228:449–61.CrossRefPubMedPubMedCentral Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg. 1998;228:449–61.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Katai H, Ishikawa T, Akazawa K, Isobe Y, et al. Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001–2007). Gastric Cancer. 2018;21:144–54.CrossRefPubMed Katai H, Ishikawa T, Akazawa K, Isobe Y, et al. Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001–2007). Gastric Cancer. 2018;21:144–54.CrossRefPubMed
17.
Zurück zum Zitat Msika S, Benhamiche AM, Jouve JL, Rat P, Faivre J. Prognostic factors after curative resection for gastric cancer: a population-based study. Eur J Cancer. 2000;36:390–6.CrossRefPubMed Msika S, Benhamiche AM, Jouve JL, Rat P, Faivre J. Prognostic factors after curative resection for gastric cancer: a population-based study. Eur J Cancer. 2000;36:390–6.CrossRefPubMed
18.
Zurück zum Zitat Ema A, Yamashita K, Sakuramoto S, Wang G, Mieno H, et al. Lymph node ratio is a critical prognostic predictor in gastric cancer treated with S-1 chemotherapy. Gastric Cancer. 2014;17:67–75.CrossRefPubMed Ema A, Yamashita K, Sakuramoto S, Wang G, Mieno H, et al. Lymph node ratio is a critical prognostic predictor in gastric cancer treated with S-1 chemotherapy. Gastric Cancer. 2014;17:67–75.CrossRefPubMed
19.
Zurück zum Zitat Kim KH, Kim YM, Kim MC, Jung GJ. Analysis of prognostic factors and outcomes of gastric cancer in younger patients: a case control study using propensity score methods. World J Gastroenterol. 2014;20:3369–75.CrossRefPubMedPubMedCentral Kim KH, Kim YM, Kim MC, Jung GJ. Analysis of prognostic factors and outcomes of gastric cancer in younger patients: a case control study using propensity score methods. World J Gastroenterol. 2014;20:3369–75.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Hosoda K, Yamashita K, Katada N, Moriya H, Mieno H, et al. Preoperative tumor size is a critical prognostic factor for patients with Borrmann type III gastric cancer. Surg Today. 2015;45:68–77.CrossRefPubMed Hosoda K, Yamashita K, Katada N, Moriya H, Mieno H, et al. Preoperative tumor size is a critical prognostic factor for patients with Borrmann type III gastric cancer. Surg Today. 2015;45:68–77.CrossRefPubMed
21.
Zurück zum Zitat Guo P, Li Y, Zhu Z, Sun Z, Lu C, et al. Prognostic value of tumor size in gastric cancer: an analysis of 2,379 patients. Tumour Biol. 2013;34:1027–35.CrossRefPubMed Guo P, Li Y, Zhu Z, Sun Z, Lu C, et al. Prognostic value of tumor size in gastric cancer: an analysis of 2,379 patients. Tumour Biol. 2013;34:1027–35.CrossRefPubMed
22.
Zurück zum Zitat Moriguchi S, Kamakura T, Odaka T, Nose Y, Maehara Y, et al. Clinical features of the differentiated and undifferentiated types of advanced gastric carcinoma: univariate and multivariate analyses. J Surg Oncol. 1991;48:202–6.CrossRefPubMed Moriguchi S, Kamakura T, Odaka T, Nose Y, Maehara Y, et al. Clinical features of the differentiated and undifferentiated types of advanced gastric carcinoma: univariate and multivariate analyses. J Surg Oncol. 1991;48:202–6.CrossRefPubMed
23.
Zurück zum Zitat Kunisaki C, Akiyama H, Nomura M, Matsuda G, Otsuka Y, et al. Clinicopathological properties of poorly differentiated adenocarcinoma of the stomach: comparison of solid- and non-solid-types. Anticancer Res. 2006;26:639–46.PubMed Kunisaki C, Akiyama H, Nomura M, Matsuda G, Otsuka Y, et al. Clinicopathological properties of poorly differentiated adenocarcinoma of the stomach: comparison of solid- and non-solid-types. Anticancer Res. 2006;26:639–46.PubMed
24.
Zurück zum Zitat Kunisaki C, Shimada H, Ono HA, Otsuka Y, Matsuda G, et al. Comparison of results of surgery in the upper third and more distal stomach. J Gastrointest Surg. 2006;10:718–26.CrossRefPubMed Kunisaki C, Shimada H, Ono HA, Otsuka Y, Matsuda G, et al. Comparison of results of surgery in the upper third and more distal stomach. J Gastrointest Surg. 2006;10:718–26.CrossRefPubMed
25.
Zurück zum Zitat Lee JW, Choi MH,Lee YJ, Song KY, Park CH, et al. Radiofrequency ablation for liver metastases in patients with gastric cancer as an alternative to hepatic resection. BMC Cancer. 2017;17:185.CrossRefPubMedPubMedCentral Lee JW, Choi MH,Lee YJ, Song KY, Park CH, et al. Radiofrequency ablation for liver metastases in patients with gastric cancer as an alternative to hepatic resection. BMC Cancer. 2017;17:185.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Petrelli F, Ghidini M, Barni S, Steccanella F, Sgroi G, et al. Prognostic role of primary tumor location in non-metastatic gastric cancer: a systematic review and meta-analysis of 50 studies. Ann Surg Oncol. 2017;24:2655–68.CrossRefPubMed Petrelli F, Ghidini M, Barni S, Steccanella F, Sgroi G, et al. Prognostic role of primary tumor location in non-metastatic gastric cancer: a systematic review and meta-analysis of 50 studies. Ann Surg Oncol. 2017;24:2655–68.CrossRefPubMed
27.
Zurück zum Zitat Choi JK, Park YS, Jung DH, Son SY, Ahn SH, et al. Clinical relevance of the tumor location-modified Lauren classification system of gastric cancer. J Gastric Cancer. 2015;15:183–90.CrossRefPubMedPubMedCentral Choi JK, Park YS, Jung DH, Son SY, Ahn SH, et al. Clinical relevance of the tumor location-modified Lauren classification system of gastric cancer. J Gastric Cancer. 2015;15:183–90.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.CrossRef Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.CrossRef
Metadaten
Titel
Borrmann Type 1 Cancer is Associated with a High Recurrence Rate in Locally Advanced Gastric Cancer
verfasst von
Ji Hyun Kim, MD, Ph.D.
Han Hong Lee, MD, Ph.D.
Ho Seok Seo, MD
Yoon Ju Jung, MD
Cho Hyun Park, MD, Ph.D.
Publikationsdatum
11.05.2018
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 7/2018
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-6509-3

Weitere Artikel der Ausgabe 7/2018

Annals of Surgical Oncology 7/2018 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.